T2 Biosystems Announces Issuance of Patents Covering T2MR Direct Detection Technology

LEXINGTON, Mass.--(BUSINESS WIRE)--T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced the U.S. Patent and Trademark Office has issued two patents adding depth and breadth to the Company’s intellectual property portfolio. These patents cover both the device and methods related to the Company’s flagship T2Candida assay and the detection of additional biological analytes, including specific drug and biomarker targets, in biological samples using the T2MR platform. “These patents illustrate the success that T2 Biosystems’ team has had in its mission to create breakthrough diagnostic detection technology that will enable the first direct detection of analytes in biological samples,” said John McDonough, President and CEO, T2 Biosystems. “Direct detection provides many advantages, including industry-leading clinical performance and the ability to run molecular, immuno and hemostasis assays on a single platform. This intellectual property covers the proprietary methods for our lead product, the T2Candida assay. Importantly, though, it extends the coverage to additional key aspects of our T2MR-based platform: detection of multiple analytes associated with disease, therapeutic management and monitoring a patient’s response to medical intervention.”